S2Medical ABFRA:S21 ROA % is 0.00% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 857 Medical Devices & Instruments companies, S2Medical AB ranks better than 50.64% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. S2Medical AB's annualizedNet Income for the quarter that ended in Dec. 2025 was €0.00 Mil.
S2Medical AB's average Total Assets over the quarter that ended in Dec. 2025 was €1.96 Mil. Therefore, S2Medical AB's annualized ROA % for the quarter that ended in Dec. 2025 was 0.00%.
The historical rank and industry rank for S2Medical AB's ROA % or its related term are showing as below:
FRA:S21'
s ROA % Range Over the Past 10 Years
Min: -107.17 Med: -46.99 Max: 20.58
Current: 0.72
During the past 10 years, S2Medical AB's highest ROA % was 20.58%. The lowest was -107.17%. And the median was -46.99%.
FRA:S21's ROA % is ranked better than 50.64% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.54
vs FRA:S21: 0.72
S2Medical AB (FRA:S21) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
S2Medical AB ROA % Related Terms
S2Medical AB ROA % Historical Data
* Premium members only.
The historical data trend for S2Medical AB's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, S2Medical AB's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
S2Medical AB ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, S2Medical AB's ROA % distribution charts can be found below:
* The bar in red indicates where S2Medical AB's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
S2Medical AB (FRA:S21) has a ROA % of 0.00% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on S2Medical AB and its competitors. According to the industry distribution chart, S2Medical AB ranks #423 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 49.4%.
Is S2Medical AB's ROA % too high?
S2Medical AB's current ROA % is 0.00%. Based on the distribution chart, S2Medical AB ranks #423 out of 857 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does S2Medical AB's ROA % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, S2Medical AB ranks #423 out of 857 companies for ROA %. This puts S2Medical AB in the upper half of its industry. The industry median ROA % is 0.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.54, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on S2Medical AB and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. S2Medical AB's current ROA % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is S2Medical AB stock overvalued right now?
S2Medical AB (FRA:S21) has a current ROA % of 0.00%. The current ROA % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For S2Medical AB (FRA:S21), the current ROA % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
S2Medical AB is a research-intensive MedTech company from Sweden. The company develops products within the entire wound healing process from debridement and granulation to re-epithelialization. products for the initial phase of a wound's healing process until the end, when the wound is completely healed. S2Medical also has in its portfolio the product NoSmell for odor removal which is procured in several different Swedish healthcare regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S21 has been successfully added to your 